Matches in Wikidata for { <http://www.wikidata.org/entity/Q92870283> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q92870283 description "article scientifique publié en 2019" @default.
- Q92870283 description "artículu científicu espublizáu n'agostu de 2019" @default.
- Q92870283 description "im August 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92870283 description "scientific article published on 23 August 2019" @default.
- Q92870283 description "wetenschappelijk artikel" @default.
- Q92870283 description "наукова стаття, опублікована 23 серпня 2019" @default.
- Q92870283 name "BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors" @default.
- Q92870283 name "BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors" @default.
- Q92870283 type Item @default.
- Q92870283 label "BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors" @default.
- Q92870283 label "BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors" @default.
- Q92870283 prefLabel "BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors" @default.
- Q92870283 prefLabel "BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors" @default.
- Q92870283 P1433 Q92870283-AA185DC3-E4DE-4944-A1CA-138D4101DFC2 @default.
- Q92870283 P1476 Q92870283-A8241720-723C-40B6-BBD8-AB61F79B24A1 @default.
- Q92870283 P2093 Q92870283-2151B617-D8FA-4AC9-9D96-D9565C172192 @default.
- Q92870283 P2093 Q92870283-24AA2B8B-1CDA-4621-80F6-D769BB8A8E71 @default.
- Q92870283 P2093 Q92870283-27C9431D-7035-420F-896B-ACF57E68A4C1 @default.
- Q92870283 P2093 Q92870283-40ECB9F7-1817-4CA1-A69E-A54F111F2843 @default.
- Q92870283 P2093 Q92870283-4D294032-DE26-4E80-852C-206A6C0CAD24 @default.
- Q92870283 P2093 Q92870283-4FE62504-B338-4790-BFAA-6BAC0804AB1C @default.
- Q92870283 P2093 Q92870283-5251B7E6-C132-4D38-8C2C-5E530264993D @default.
- Q92870283 P2093 Q92870283-5DAB1F8D-1954-4155-8401-CCB79F3526A7 @default.
- Q92870283 P2093 Q92870283-8A5EB8BB-2AA1-4747-8429-B121716D6F49 @default.
- Q92870283 P2093 Q92870283-AACD9E38-1A5D-4F40-9C93-9FBB41CA7AB8 @default.
- Q92870283 P2093 Q92870283-BD50FF8C-1F98-465C-9359-4FEB4CAD7DCC @default.
- Q92870283 P2093 Q92870283-BE57E557-423F-4606-8101-235CEC1951C5 @default.
- Q92870283 P2093 Q92870283-C2EAB078-3E05-4363-8F00-A0EA7F427BF9 @default.
- Q92870283 P2093 Q92870283-D6A43B60-AE34-4E6D-96F3-D4F5FAE6A0DB @default.
- Q92870283 P2093 Q92870283-DF821CD1-6B04-452D-A07C-113DF49EA8DE @default.
- Q92870283 P2093 Q92870283-EC693C07-41BF-4028-984F-86871781935D @default.
- Q92870283 P2093 Q92870283-F8A1EC86-15B1-4AA6-AAD2-BDD899308333 @default.
- Q92870283 P304 Q92870283-A14FC720-A9F9-405F-8C3C-D006DB372884 @default.
- Q92870283 P31 Q92870283-36A61479-1385-4B50-B315-56FCCA3A674F @default.
- Q92870283 P356 Q92870283-9FCE5C46-1964-4584-B929-E0C5D7E1DA24 @default.
- Q92870283 P433 Q92870283-26A22FC7-6CDE-45EB-8350-9692072CD722 @default.
- Q92870283 P478 Q92870283-C6549772-24F2-4D39-A171-7EE69F7C1DE7 @default.
- Q92870283 P577 Q92870283-16AC9D79-EE19-42A3-A495-BAF05BA593D9 @default.
- Q92870283 P698 Q92870283-9AD31A3B-FD67-404F-83BD-73885A68200C @default.
- Q92870283 P356 J.JAAD.2019.08.045 @default.
- Q92870283 P698 31449902 @default.
- Q92870283 P1433 Q15757046 @default.
- Q92870283 P1476 "BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors" @default.
- Q92870283 P2093 "Anne Braun" @default.
- Q92870283 P2093 "Antonio Cozzio" @default.
- Q92870283 P2093 "Bernhard Mani" @default.
- Q92870283 P2093 "Christian D Sadik" @default.
- Q92870283 P2093 "Christoph Hammers" @default.
- Q92870283 P2093 "David Bomze" @default.
- Q92870283 P2093 "Detlef Zillikens" @default.
- Q92870283 P2093 "Enno Schmidt" @default.
- Q92870283 P2093 "Fiamma Berner" @default.
- Q92870283 P2093 "Lukas Flatz" @default.
- Q92870283 P2093 "Marie-Therese Abdou" @default.
- Q92870283 P2093 "Mirjam Fässler" @default.
- Q92870283 P2093 "Omar Hasan Ali" @default.
- Q92870283 P2093 "Sandra S Ring" @default.
- Q92870283 P2093 "Shirin Emtenani" @default.
- Q92870283 P2093 "Stefan Diem" @default.
- Q92870283 P2093 "Wolfram Jochum" @default.
- Q92870283 P304 "854-861" @default.
- Q92870283 P31 Q13442814 @default.
- Q92870283 P356 "10.1016/J.JAAD.2019.08.045" @default.
- Q92870283 P433 "4" @default.
- Q92870283 P478 "82" @default.
- Q92870283 P577 "2019-08-23T00:00:00Z" @default.
- Q92870283 P698 "31449902" @default.